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in any medium, proObjectives: We investigated the prevalence, incidence and predictors of new peri-
pheral neuropathy episodes in previously untreated, symptomatic HIV-infected
Ugandan/Zimbabwean adults initiating zidovudine-based antiretroviral therapy (ART).
Design: An open-label, multicentre, randomized trial.
Methods: Peripheral neuropathy was self-reported at 12-weekly clinic visits. Cox
regression models (excluding participants reporting preexisting peripheral neuropathy
at ART initiation), considered sex; pre-ART WHO stage, age and CD4þ cell count;
CD4þ cell count versus no CD4þ cell count monitoring; and time-updated CD4þ cell
count, weight and use of stavudine, isoniazid and didanosine.
Results: Four hundred and twenty-one out of 3316(13%) patients reported preexisting
peripheral neuropathy at ART initiation. Median (interquartile range, IQR) follow-up in
2895 participants without preexisting peripheral neuropathy was 4.9 (4.7–5.4) years.
Three hundred and fifty-four (12%) took stavudine as first-line substitution and 518
(18%) took isoniazid during follow-up. Two hundred and ninety (11%) participants
developed a new peripheral neuropathy episode, an incidence of 2.12 per 100 person-
years. Eighteen (0.1%) had a grade 3/4 episode. Independent predictors of peripheral
neuropathy were current stavudine use [adjusted hazard ratio (a)HR 4.16 (95%
confidence interval, 95% CI 3.06–5.66], current isoniazid use [aHR 1.59 (95% CI
1.02–2.47)] and current didanosine use [aHR 1.60 (95% CI 1.19–2.14)]. Higher risks
were independently associated with higher pre-ART weight [aHR (perþ5 kg) 1.07 (95%
CI 1.01–1.13)] and older age aHR (per 10 years older) 1.29 (95% CI 1.12–1.49), but
there was no significant effect of sex (P¼0.13), pre-ART CD4þ cell count (P¼0.91) or
CD4þ cell count monitoring (P¼0.73).
Conclusion: Current stavudine, didanosine or isoniazid use continue to increase
peripheral neuropathy risks, as does older age and weight at ART initiation; however,
we found no evidence of increased risk in women in contrast to previous studies. The
incidence of peripheral neuropathy may now be lower in ART programmes, as
stavudine and didanosine are no longer recommended. All patients receiving isoniazid,
either as part of antituberculosis (TB) chemotherapy or TB-preventive therapy, should
receive pyridoxine as recommended in national guidelines.
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Peripheral neuropathy is the most common neurological
disorder in people with HIV infection and is associated
with both HIV disease and antiretroviral therapy (ART).
In the pre-ARTera, peripheral neuropathy was associated
with advanced HIV disease and severe immuno-
suppression [1]. The introduction of combination ART
in high-income countries in the 1990s led to a reduction
in overall incidence of neurological complications
including peripheral neuropathy [2]. However, periph-
eral neuropathy is also a recognized adverse effect
associated with the use of nucleoside analogue reverse
transcriptase inhibitors such as stavudine and didanosine
[3]. In resource-limited settings, stavudine in particular
has been used more frequently in combination ART due
to its low cost. However, both HIV and ART-associated
peripheral neuropathy can coexist and it may be difficult
to distinguish between them clinically. Additional factors
such as older age, female sex, low CD4þ cell count,
nutritional deficiencies, antituberculosis (anti-TB) drugs,
high viral load, chemotherapy and alcohol use have been
identified as risk factors for newly diagnosed peripheral
neuropathy in previous studies [4–7].
Sensory neuropathies are the most common manifes-
tation of peripheral neuropathy and are characterized by
pain and abnormal sensations such as numbness, pricking
or burning. Pain associated with peripheral neuropathy
has been identified as a major source of discomfort (with a
consequent impact on quality of life) and a limiting factor
in patients remaining on and/or adhering to antiretroviral
treatment [8]. Thus, peripheral neuropathy has the
potential to increase rates of first-line failure and hence
future treatment costs.
Screening tools for peripheral neuropathy have been
developed including the Brief Peripheral Neuropathy
Screen (BPNS) for reported symptoms, quantitative tests
and/or clinical assessments administered by clinician or
patients. However, these tools have been less frequently
used in resource-limited settings. The few existing studies
in sub-Saharan Africa have shown widely varying
prevalence of 1–60% with HIV or ART-related
peripheral neuropathy [7,9–15]. The post-ART inci-
dence rates for peripheral neuropathy were also not
consistent across several studies, varying between 0.9 and
40 per 100 person-years in a review [15]. The differences
probably reflect varying definitions, different clinical
settings, short follow-up time and the lack of a standard
validated screening tool.
Although use of stavudine has now been phased out in
most countries in sub-Saharan Africa following WHO
guidelines, resource-limited settings still face challenges
from peripheral neuropathy due to a high prevalence of
other risk factors such as advanced HIV disease, burden of
TB and malnutrition. To further understand the factorspyright © Lippincott Williams & Wilkins. Unauthoassociated with peripheral neuropathy, and in particular
to examine the independent risks associated with use of
stavudine, didanosine and isoniazid, we carried out a
secondary analysis of the data from the Development of
Antiretroviral Therapy (DART) trial in Uganda and
Zimbabwe.Materials and methods
DART was an open, randomized controlled trial
comparing two management strategies for monitoring
ART: routine laboratory and clinical monitoring
(12-weekly CD4þ cell count and haematology and
biochemistry tests) versus clinically driven monitoring
(haematology or biochemistry tests only if clinically
indicated) [16]. Between September 2003 and October
2004, the trial enrolled 3316 symptomatic (WHO stage
2–4) HIV-infected ART-naive adults aged at least 18
years with CD4þ cell counts less than 200cells/ml in
Uganda (two centres with one satellite) and Zimbabwe
(one centre). At enrolment, all participants started triple-
drug combination ART with zidovudine/lamuvidine
along with either tenofovir (in 2003/2004) or nevirapine
or abacavir (2004 only) following WHO guidelines at
the time [17]. Stavudinewas used as a first-line substitution
and didanosine as part of second-line treatment according
to WHO guidelines. A second randomization compared
structured treatment interruptions with continuous ART
in 813 participants until March 2006, when it was
terminated and participants on structured treatment
interruptions were moved to continuous ART [18].
Pre-ART clinical and demographic characteristics were
recorded. All participants saw a doctor and had a routine
full blood count with white cell differential and
lymphocyte subsets at screening, weeks 4 and 12 and
then every 12 weeks, although in the clinically driven
monitoring arm, results were not returned to the trial
doctors unless there was a grade 4 abnormality or if the
results were requested for clinical reasons (CD4þ cell
counts were never returned). The doctor visit included
specific elicitation of symptoms of peripheral neuropathy
as a case record form (CRF) data item, and if present,
clinical symptoms were described and graded as follows:
grade 1 - mild paraesthesia, numbness, pain or weakness,
not requiring treatment; grade 2, moderate paraesthesia,
numbness or pain, objective weakness, requiring analge-
sic; grade 3, severe paraesthesia, numbness or pain or
weakness, interfering with normal activity, requiring a
narcotic; grade 4, intolerable paraesthesia, numbness or
pain resulting in incapacity, paralysis or being unable to
walk, despite narcotics. There was no attempt made to
distinguish HIV and ART-associated peripheral neuro-
pathy symptoms. Other clinical events were also
documented at follow-up visits. Participants’ adherence
to ART was assessed by pill counts and a structuredrized reproduction of this article is prohibited.
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clinic visit. ART substitutions could be made for toxicity
at the discretion of the treating physician, for example
stavudine for zidovudine in the case of severe (grade 3–4)
anaemia. Anti-TB drugs included isoniazid according to
national guidelines on TB treatment, which also advocate
the use of pyridoxine to lessen the risk of peripheral
neuropathy.
Statistical analysis
Our aim was to characterize prevalence, cumulative
incidence and predictors of new peripheral neuropathy
episodes in previously untreated adults initiating ART;
we therefore excluded all individuals reporting pre-
existing peripheral neuropathy at ART initiation from
analyses. The primary outcome was time from ART
initiation to first peripheral neuropathy episode, regard-
less of severity/grade, and censoring at the earliest of loss
of follow-up, death or 31 December 2008 (end of trial).
Potential demographic and clinical explanatory variables
were summarized according to whether or not the
participant ever experienced an episode of peripheral
neuropathy, using frequencies and percentages for categ-
orical variables, and means and standard deviations or
medians and inter-quartile ranges for continuous variables.
The Kaplan–Meier method was used to estimate the
incidence of peripheral neuropathy, with Cox models
used to assess the following pre-ART risk factors: age
(18–35, 35–50, more than 50 years), sex (male, female),
WHO disease stage [2–4], weight and CD4þ cell count.
Following a reviewer’s suggestion, we further assessed
whether pre-ART height was a risk factor for the
development of peripheral neuropathy. We investigated
nonlinearity of continuous CD4þ cell count, weight and
age using fractional polynomials regression [19].We fitted
univariable and multivariable models selecting by back-
ward elimination (exit probability of 0.1). In separate
time-dependent Coxmodels, we then also considered theCopyright © Lippincott Williams & Wilkins. Unaut
Table 1. Pre-antiretroviral therapy characteristics associated with cumul
Cumulative incidence of PN Present n¼290 (100%
Randomization in main DART trial
Laboratory and clinical monitoring 150 (52%)
Clinical monitoring only 140 (48%)
Sex
Female 193 (67%)
Age at ART initiation (years) median (IQR) 37 (33–43)
CD4þ cell count (cells/ml) median (IQR) 82 (34–133)
WHO disease stage
2 50 (17%)
3 171 (59%)
4 69 (59%)
Weight (kg)
<45 21 (7%)
45–55 93 (32%)
55–65 98 (34%)
More than 65 77 (27%)
ART, antiretroviral therapy; IQR, interquartile range; PN, peripheral neuroimpact of time-updated factors, CD4þ cell count, weight,
stavudine use, isoniazid use and didanosine use, adjusted
for main DARTrandomizedmonitoring strategy and pre-
ART factors found to be independent predictors in the
model for pre-ART factors above. Isoniazid was included
as both a two-level variable (current use vs. no current
use) and a three-level variable with levels no use, isoniazid
with pyridoxine and isoniazid without pyridoxine.
We further summarized the history of isoniazid use as
a four-level variable: never used; current use; last used
0–90 days ago; and last used more than 90 days ago.
Statistical analysis was performed using Stata version 12
(Stata Corp., College Station, Texas, USA) and R version
2.15.1.Results
Characteristics of study population by peripheral
neuropathy status
Three thousand three hundred and sixteen patients were
enrolled in the DART trial between January 2003 and
October 2004. Four hundred and twenty-one (13%)
reported preexisting peripheral neuropathy at ART
initiation leaving 2895 participants in this analysis with
a median (interquartile range, IQR) 4.9 (4.7–5.4) years
follow-up after ART initiation. All participants initiated
ART with zidovudine/lamivudine coformulated as
combivir and either tenofovir 2200 (76%), nevirapine
457 (16%) or abacavir 238 (8%). Three hundred and fifty-
four (12%) took stavudine, 518 (18%) took isoniazid and
396 (14%) took didanosine during follow-up. Pyridoxine
(vitamin B complex) was prescribed along with isoniazid
used as TB treatment or prophylaxis in 228 (44%) of those
taking isoniazid. Overall, 290 (11%) participants devel-
oped a new peripheral neuropathy episode on ART;
67% were women, median age was 37 years and median
(IQR) pre-ART CD4þ cell count was 82 cells/ml
(34–133 cells/ml), see Table 1. One hundred andhorized reproduction of this article is prohibited.
ative incidence of peripheral neuropathy.
) Absent n¼2605 (100%) Preexisting n¼421 (100%)
1299 (50%) 207 (49%)
1306 (50%) 214 (51%)
1697 (65%) 266 (63%)
36 (31–42) 39 (34–43)
88 (33–142) 90 (33–136)
567 (22%) 56 (13%)
1458 (56%) 235 (56%)
580 (22%) 130 (31%)
264 (10%) 34 (8%)
913 (35%) 136 (32%)
899 (35%) 151 (36%)
510 (20%) 97 (23%)
pathy.
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neuropathy episode exclusively on a zidovudine-based
regimen, that is without ever receiving stavudine or
didanosine; 21 out of 134 had received isoniazid.
Cumulative incidence of peripheral neuropathy
over time
Of 290 participants developing new peripheral neuro-
pathy episodes on ART, 118 (41%) had at most grade 1
peripheral neuropathy (including 16 participants with no
grade ever reported), 154 (53%) at most grade 2
peripheral neuropathy and 18 (6%) reported grade 3 or
4 peripheral neuropathy at some point during follow-up.
Nine out of 18 grade 3/4 peripheral neuropathy events
occurred by 96 weeks. The overall incidence of any grade
peripheral neuropathy was 2.12 per 100 person-years
(0.10/100 person-years for grade 3/4) and was greater in
the first year on ART (P< 0.001). Kaplan–Meier plots
showing the time to first post-ARTepisode of peripheral
neuropathy are shown in Fig. 1, broken down by age and
weight at ART initiation. In time-dependent analyses,
the rates were higher for participants who ever used
stavudine, for participants who ever used didanosine and
for participants who ever used isoniazid, particularly if
they were not recorded as having taken concomitant
pyridoxine (Table 2), which was given as 25mg/day
according to national guidelines. Prevalence of peripheral
neuropathy during follow-up at 6 months and 1, 2, 3, 4,
5, 6 years was 0.7, 0.7, 0.4, 0.4, 0.1, 0.5 and 0.5,
respectively, Fig. 2.
Pre-antiretroviral therapy risk factors for
development of peripheral neuropathy on
antiretroviral therapy
The results of the unadjusted and adjusted Cox regression
models are summarized in Table 3. Independently, older
age at ART initiation [adjusted hazard ratio, aHR, 1.25 per
10 year older, 95% confidence interval (95% CI) 1.09–
1.45] and increasing weight at ART initiation (aHR 1.06
per 5 kgheavier, 95%CI1.01–1.12) significantly increased
the risk of peripheral neuropathy on ART. There was no
evidence of an effect of sex, height, WHO stage or CD4þ
cell count at ART initiation, or of randomized CD4þ cell
count monitoring strategy (P> 0.2).
Time-updated factors associated with
development of peripheral neuropathy
Independently in the time-updated model (Table 3),
current use of stavudine (aHR 4.16, 95% CI 3.06–5.66);
current use of isoniazid (aHR 1.57, 95% CI 1.00–2.44);
and current use of didanosine (aHR 1.60, 95% CI 1.19–
2.14) increased the risk of developing peripheral
neuropathy. Investigating effect modification by con-
current use of pyridoxine, in a multivariable sensitivity
analysis, we found a lower risk of peripheral neuropathy
associated with current use of isoniazid with pyridoxine
(aHR 1.23, 95% CI 0.46–3.32) than isoniazid without
pyridoxine (aHR 1.67, 95% CI 1.02–2.71) but nor werepyright © Lippincott Williams & Wilkins. Unauthothere sufficient events to determine whether or not this
risk really differed (heterogeneity P¼ 0.59). Even after
adjusting for these time-dependent factors, greater
peripheral neuropathy risks associated with older age
and heavier weight at ART initiation remained
(P 0.001, Table 3). After adjusting for these pre-
ART factors, and time-updated stavudine, didanosine and
isoniazid use, there was no evidence that the risk of
peripheral neuropathy depended on sex (aHR 1.07, 95%
CI 0.77–1.49), time-updated CD4þ cell count (aHR
1.01 per 100 cells/ml higher, 95% CI 0.82–1.24) or
randomized CD4þ cell count monitoring strategy (aHR
0.95, 95% CI 0.76–1.20), height per cm higher (aHR
0.99, 95% CI 0.97–1.01). In a further sensitivity analysis,
we also considered previous isoniazid use: compared with
never having used isoniazid, the risk of peripheral
neuropathy tended to be higher for current isoniazid use
(adjusted for other factors in the time-updated multi-
variable model in Table 3 aHR 1.54, 95% CI 0.99–2.40)
than last use within the prior 0–90 days (aHR 0.27, 95%
CI 0.04–1.90) or more than 90 days previously (aHR
0.88, 95% CI 0.55–1.41). However, the numbers
developing peripheral neuropathy in the latter two
groups (1 and 21 events, respectively) were few, and there
was no formal evidence for variation in peripheral
neuropathy risk according to time since last isoniazid use
(heterogeneity P¼ 0.07).Discussion
The results from this large cohort of HIV-infected
individuals initiating ART with zidovudine-based regi-
mens in sub-Saharan Africa demonstrate that use of
isoniazid, didanosine, stavudine as well as higher pre-
ARTweight and greater age are the key risk factors for
development of new peripheral neuropathy on ART;
however, we found no evidence of increased risk in
women in contrast to previous studies. Further, risks of
peripheral neuropathy appear to be increased even if
pyridoxine is given with isoniazid as per national
guidelines. A systematic review of 48 studies (including
randomized trials) concluded that it was unclear whether
or not use of pyridoxine with isoniazid decreases
peripheral neuropathy risk [20]. A further issue is that
pyridoxine dosing recommendations differ in different
countries andmay also impact peripheral neuropathy risk:
however, in Uganda and Zimbabwe, 25mg/day is the
recommended dose in national guidelines. Actual dose
was not recorded on trial CRFs, so we are unable to
investigate the impact of dose further. Clinicians may
recommend a variety of nutritional supplements includ-
ing vitamin B, but data supporting their use in prevention
or treatment of peripheral neuropathy remain sparse [21].
We did not collect data on nutritional supplements so
cannot assess this Vitamin B6 toxicity due to additional
nutritional supplements or other dietary intake of naturalrized reproduction of this article is prohibited.
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Fig. 1. Cumulative hazard of 2895 participants over time from antiretroviral therapy initiation. (a) Overall, (b) stratified by age
and (c) stratified by weight.food sources of vitamins, such as nuts, could theoretically
cause neuropathic pain. This toxicity is unlikely to have
occurred in our study, as vitamin B6 intake was likely
inadequate, for example nutritional supplements would
have been limited due to cost and access and most nuts areCopyright © Lippincott Williams & Wilkins. Unautoften processed resulting in loss of some nutrients;
however, it might be considered in other settings.
We found, as has been shown in other studies, that
stavudine significantly increased the risk of peripheralhorized reproduction of this article is prohibited.
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Table 2. Peripheral neuropathy event rate by exposure to specific drugs.
Factor N (%) ever used Events N¼290
Event rate per 100
person-years (95% CI)
Current use of stavudine No 235 1.8 (1.6–2.1)
Yes 354 (12%) 55 5.8 (4.5–7.6)
Current use of didanosine No 233 2.0 (1.7–2.2)
Yes 396 (14%) 57 3.1 (2.4–4.0)
Current use of isoniazid Yes with pyridoxine 153 (5%) 4 3.5 (1.4–8.3)
Yes without pyridoxine 365 (13%) 18 4.6 (2.9–7.4)
No 263 2.0 (1.8–2.3)
Current use of isoniazid No 267 2.0 (1.8–2.3)
Yes 518 (18%) 23 4.3 (2.9–6.5)
Use of isoniazid No 245 2.1 (1.9–2.4)
Current use 518 (18%) 23 4.3 (2.9–6.5)
Used in the last 0–90 days 1 1.0 (0.1–5.7)
Last used >90 days ago 21 1.5 (1.0–2.3)
CI, confidence interval.neuropathy [9,10,22–24]. The association of didanosine
with peripheral neuropathy is also consistent with
previous studies from high-income countries [5].
However, not all studies have found higher rates of
peripheral neuropathy in those receiving didanosine, for
example Moore et al. [3] found peripheral neuropathy to
be associated with combined use of didanosine and
stavudine but not didanosine alone, and Kelleher et al.
[25] found no association of didanosine with peripheral
neuropathy in a clinical trial using higher didanosine
doses than now recommended.
Post-ART prevalence in resource-limited settings from
previous studies has been estimated between 20 and
50% [13–15] but with a wide variation noted in a
previous systematic review [15]. Thirteen percent of the
DART trial population reported preexisting peripheral
neuropathy at ART initiation, which is lower than thepyright © Lippincott Williams & Wilkins. Unautho
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Fig. 2. Prevalence of peripheral neuropathy in participants
not reporting peripheral neuropathy (any grade) at enrol-
ment over time from antiretroviral therapy initiation.post-ART peripheral neuropathy prevalence from
previous studies, which however highlights the import-
ance of nondrug-based factors. On ART, prevalence in
those not reporting preexisting peripheral neuropathy at
ART initiation was nearly 1% at subsequent follow-up
visits. Overall, pre-ART prevalence is more similar to
studies from high-income settings [3,24,26] and one
study in Asia [27], and lower than other studies from
resource-limited settings [7,9,23,28] for reasons that are
unclear. The differences in on-ART prevalence estimates
may be due to a high proportion of stavudine use in other
ART programmes in resource-limited settings, whereas
this was only used as a first-line substitution in DART.
Although less use of stavudinemay explain at least some of
this difference, 7% of those initiating ART and never
receiving stavudine or didanosine during follow-up
developed peripheral neuropathy compared with 20%
using zidovudine-based regimens in Shurie and Deribew
[28]; assessment methods for peripheral neuropathy could
therefore also play a role. Importantly, most new episodes
on ART were mild/moderate and severe peripheral
neuropathy was rare in this study. The incidence of
peripheral neuropathy should now be lower in the
general HIV-infected population, as stavudine is no
longer recommended even as a first-line substitution in
the most recent WHO guidelines [29], nor is didanosine
recommended in second-line.
The incidence of peripheral neuropathy in our study was
higher in the first year on ART than subsequently, with an
incidence less than 1% per annum after the first year on
ART. Our findings are similar to other studies in high-
income settings showing that the risk of peripheral
neuropathy is relatively low after the first 6–12months on
ART. For example, in the Delta trial, the estimated
incidence rate of peripheral neuropathy peaked in first 90
days and then declined [30]; Lichtenstein et al. [31] also
observed higher peripheral neuropathy incidence in first
6 months on ART, which subsequently dropped and then
remained low with increasing time on ART, even in
severely immunosuppressed HIV-infected individuals.rized reproduction of this article is prohibited.
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Table 3. Baseline and time-updated predictors of peripheral neuropathy in 2895 persons not reporting peripheral neuropathy at antiretroviral
therapy initiation.
Univariable models
Multivariable model
including pre-ART
factors onlya
Multivariable model
including time-updated
factorsa
Unadjusted
HR 95% CI P
Adjusted
HR 95% CI P
Adjusted
HR 95% CI P
Female vs. male 1.06 (0.83–1.35) 0.6
Age (per 10 years older) 1.27 (1.11–1.47) 0.001 1.25 (1.09–1.45) 0.002 1.29 (1.12–1.49) <0.001
WHO stage
Stage 2 0.76 (0.55–2.02)
Stage 3 1(ref) – 0.2
Stage 4 1.00 (0.76–1.33)
Pre-ART CD4þ cell count
(per 100 cells/ml higher)
0.94 (0.77–1.14) 0.5
Pre-ART weight
(per 5 kg heavier) 1.08 (1.02–1.13) 0.01 1.06 (1.01–1.12) 0.02 1.07 (1.01–1.13) 0.001
No CD4þ vs. CD4þ cell
count monitoring
0.93 (0.74–1.18) 0.6
Current CD4þ cell count
(per 100 cells/ml higher)
0.93 (0.76–1.12) 0.4
Currently on stavudine
Yes vs. no 3.82 (2.82–5.17) <0.001 4.16 (3.06–5.66) <0.001
Currently on isoniazid 1.75 (1.12–2.72) 0.01 1.57 (1.00–2.44) 0.05
Isoniazid: sensitivity analysis
Not on isoniazid 1(ref) 0.04b 1(ref) 0.11c
Isoniazid with pyridoxine 1.46 (0.54–3.92) 0.46 1.23 (0.46–3.32) 0.68
Isoniazid without pyridoxine 1.83 (1.13–2.97) 0.02 1.67 (1.02–2.71) 0.04
Currently on didanosine
Yes vs. no 1.51 (1.12–2.02) 0.01 1.60 (1.19–2.14) 0.002
Pre-ART height per cm higher 1.00 (0.98–1.01) 0.6 0.99 (0.97–1.01) 0.2
There was no evidence of nonlinearity in the effect of any continuous factors tested using fractional polynomials (P>0.05). ART, antiretroviral
therapy; CI, confidence interval; HR, hazard ratio; PN, peripheral neuropathy.
aBackwards elimination (exit P¼0.1); time-updated models used factors that independently predicted PN in the pre-ART model.
bGlobal (2df) P¼0.04; test for heterogeneity of effect of isoniazid according to concomitant use of pyridoxine or not P¼0.68.
cGlobal (2df) P¼0.11; test for heterogeneity of effect of isoniazid according to concomitant use of pyridoxine or not P¼0.59.However, as above, overall, we observed a lower post-
ART peripheral neuropathy incidence than more recent
studies in Africa [22,23,32,33] and one USA study [34].
In our study, pre-ARTage and weight were independent
risk factors for peripheral neuropathy, whether or not
time-updated drug exposure was also adjusted for.
Previous studies have shown peripheral neuropathy
associations with age consistently [35–37] and also with
either weight or BMI; we observed higher peripheral
neuropathy risk in heavier individuals comparable to
previous studies [10,38]. Models including pre-ART
BMI rather than weight gave similar inferences in our data
(not shown). The association of peripheral neuropathy
with pre-ART weight may be explained by poor
peripheral nerve distribution in the fat beneath the skin
among overweight individuals. Previous studies have
shown that greater height increases the risk of peripheral
neuropathy [39]. This result is not replicated in our study,
but the significant association of BMI with risk of
peripheral neuropathy development is probably indicative
of the impact of weight. In contrast to our study, previous
studies have also found associations between peripheral
neuropathy and sex [33,39,40] and pre-ART CD4þ or
time-updated CD4þ cell count [3,30]. For example,Copyright © Lippincott Williams & Wilkins. UnautMehta et al. [33] found that women were 10 times more
likely to develop peripheral neuropathy in the first year on
ART in a Kenyan cohort (63% initiating stavudine-based
regimens), an association that persisted after adjustment
for age, pre-ART BMI and initial stavudine. The BPNS
used in this Kenyan study combines patient assessment of
symptoms with clinical assessment of vibration sense and
ankle deep tendon reflexes; one explanation for the
significantly higher rates in women could have been
greater reporting of symptoms. Currier et al. [41] also
showed that women more often discontinued ART due
to adverse events including peripheral neuropathy more
frequently than men. Previous associations between
peripheral neuropathy and CD4þ cell count are from the
precombination ART era: the lack of association in our
study support the findings by Wadley et al. [10] that
suggest CD4þ cell count may be a less important
predictor in the context of combination ART.
Most peripheral neuropathy events observed were mild; it
is unlikely that we would have missed severe cases. One
question is how these generally mild cases are best
managed. Novel therapies may be of limited efficacy and
are often unavailable in resource-limited settings with the
highest peripheral neuropathy burden [42]. As peripheralhorized reproduction of this article is prohibited.
Co
2586 AIDS 2014, Vol 28 No 17neuropathy is typically chronic, and ART and/or TB
treatment is needed for other aspects of health, focusing
on self-management strategies to control response to pain
is essential [43]. There is an analogy with cancer, wherein
chemotherapy-induced peripheral neuropathy is viewed
by some as an acceptable consequence of successful cancer
therapy, which nevertheless also needs long-term self-
management strategies that could be translated into HIV
infection [21,44].
One limitation of our study is that we assessed peripheral
neuropathy only on the basis of clinical diagnosis. Patients
were asked at each 12-weekly visit of any symptoms
consistent with peripheral neuropathy, which were then
graded by the doctor taking into consideration other
causes based on a physical examination conducted at each
visit; thus, our outcome is based on self-report in contrast
to other studies such as the BPNS used in Mehta et al.
[11], which incorporated objective measures as well as
reported symptoms. Estimates of prevalence and inci-
dence will depend on the criteria used to define
peripheral neuropathy; nevertheless, the fact that we
found the expected predictors of pre-ART age, weight
and stavudine use suggests that this outcome was
reasonably well ascertained. The majority (94%) of
peripheral neuropathy events reported were grade 1/2; it
is possible that on the basis of our simple clinical criteria,
some cases with mild symptoms were missed, but it is
unlikely that many severe cases were not included. We
were unable to definitively identify whether peripheral
neuropathy risks differ significantly between isoniazid
with pyridoxine and isoniazid without pyridoxine;
although it is possible that some patients were given
pyridoxine without this being recorded, all concomitant
medications were requested on trial CRFs, and point
estimates suggested that isoniazid-associated peripheral
neuropathy risk could be substantially reduced by adding
pyridoxine. Nonadherence to ART may also increase the
risk of peripheral neuropathy, and conversely, peripheral
neuropathy could have adverse effects on adherence and/
or quality of life. These factors may have compounded the
risk of peripheral neuropathy, but are difficult to
adequately disentangle. However, despite the limitations,
our findings are consistent with more recent studies, and
are also on a very large (3000) cohort, with very long
(5 year) follow-up. In contrast, previous studies from
resource-limited settings were mainly cross-sectional in
nature or had short follow-up and/or individuals initiated
ART exclusively with stavudine.
Conclusion
Isoniazid, stavudine and didanosine increase the inci-
dence of peripheral neuropathy, independently of pre-
ART age and weight. Of note, among those taking
isoniazid, we were unable to show definitively that the
risk of peripheral neuropathy was lower in those who also
took pyridoxine versus those who did not; and we did not
find any evidence of increased risk in women orpyright © Lippincott Williams & Wilkins. Unauthoaccording to pre-ART or current CD4þ cell count in
contrast to previous studies. Our study highlights that
screening for peripheral neuropathy may be important in
in older participants and those with higher BMI initiating
ART. Although didanosine is no longer recommended by
WHO for second-line, it is still being used in some
patients; other second-line drugs might be preferable in
higher risk patients, particularly if receiving isoniazid
for treatment or as prophylaxis. The more frequent
occurrence of HIV and TB coinfection in sub-Saharan
Africa may require further consideration in screening for
peripheral neuropathy.Acknowledgements
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